Milestone Pharmaceuticals (NASDAQ:MIST) Earns "Sell (D-)" Rating from Weiss Ratings

Key Points

• Milestone Pharmaceuticals (NASDAQ:MIST) has received a "Sell (D-)" rating from Weiss Ratings, highlighting concerns about the company's performance.
• Wells Fargo has initiated coverage with an "overweight" rating and a price target of $4.00, while the consensus rating among analysts is currently "Hold" with an average target price of $4.50.
• Institutional investors have significantly increased their stakes in Milestone Pharmaceuticals, which may indicate confidence in the company's future prospects despite its recent stock price decline.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report)'s stock had its "sell (d-)" rating reiterated by analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Wells Fargo & Company started coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, September 11th. They set an "overweight" rating and a $4.00 price objective for the company. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $4.50.

Milestone Pharmaceuticals Trading Down 3.8%

Shares of Milestone Pharmaceuticals stock opened at $2.00 on Wednesday. The firm has a market cap of $169.98 million, a PE ratio of -2.38 and a beta of 0.61. The stock has a 50 day moving average of $1.80 and a 200 day moving average of $1.56. Milestone Pharmaceuticals has a 12 month low of $0.63 and a 12 month high of $2.75.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.02). As a group, equities research analysts forecast that Milestone Pharmaceuticals will post -0.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in MIST. Propel Bio Management LLC purchased a new stake in Milestone Pharmaceuticals in the 1st quarter valued at about $1,161,000. Simplify Asset Management Inc. boosted its holdings in shares of Milestone Pharmaceuticals by 16.5% in the second quarter. Simplify Asset Management Inc. now owns 990,000 shares of the company's stock valued at $1,921,000 after purchasing an additional 140,000 shares during the period. Valeo Financial Advisors LLC grew its stake in Milestone Pharmaceuticals by 553.5% in the second quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company's stock worth $254,000 after purchasing an additional 110,699 shares in the last quarter. XTX Topco Ltd grew its stake in Milestone Pharmaceuticals by 209.5% in the second quarter. XTX Topco Ltd now owns 160,963 shares of the company's stock worth $312,000 after purchasing an additional 108,959 shares in the last quarter. Finally, Walleye Capital LLC bought a new stake in Milestone Pharmaceuticals during the 1st quarter valued at $74,000. Hedge funds and other institutional investors own 86.18% of the company's stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.